{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:31:34Z","timestamp":1778869894270,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017M3A9G7072864"],"award-info":[{"award-number":["NRF-2017M3A9G7072864"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A chronic, local inflammatory milieu can cause tissue fibrosis that results in epithelial-to-mesenchymal transition (EMT), endothelial-to-mesenchymal transition (EndMT), increased abundance of fibroblasts, and further acceleration of fibrosis. In this study, we aimed to identify potential mechanisms and inhibitors of fibrosis using 3D model-based phenotypic screening. We established liver fibrosis models using multicellular tumor spheroids (MCTSs) composed of hepatocellular carcinoma (HCC) and stromal cells such as fibroblasts (WI38), hepatic stellate cells (LX2), and endothelial cells (HUVEC) seeded at constant ratios. Through high-throughput screening of FDA-approved drugs, we identified retinoic acid and forskolin as candidates to attenuate the compactness of MCTSs as well as inhibit the expression of ECM-related proteins. Additionally, retinoic acid and forskolin induced reprogramming of fibroblast and cancer stem cells in the HCC microenvironment. Of interest, retinoic acid and forskolin had anti-fibrosis effects by decreasing expression of \u03b1-SMA and F-actin in LX2 cells and HUVEC cells. Moreover, when sorafenib was added along with retinoic acid and forskolin, apoptosis was increased, suggesting that anti-fibrosis drugs may improve tissue penetration to support the efficacy of anti-cancer drugs. Collectively, these findings support the potential utility of morphometric analyses of hepatic multicellular spheroid models in the development of new drugs with novel mechanisms for the treatment of hepatic fibrosis and HCCs.<\/jats:p>","DOI":"10.1038\/s41598-021-90263-x","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T10:03:15Z","timestamp":1621936995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Identification of hepatic fibrosis inhibitors through morphometry analysis of\u00a0a hepatic multicellular spheroids model"],"prefix":"10.1038","volume":"11","author":[{"given":"Yeonhwa","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-Ram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haeng Ran","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"90263_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Investig. 115, 209\u2013218. https:\/\/doi.org\/10.1172\/JCI24282 (2005).","journal-title":"J. Clin. Investig."},{"key":"90263_CR2","doi-asserted-by":"publisher","unstructured":"Weiskirchen, R., Weiskirchen, S. & Tacke, F. Recent advances in understanding liver fibrosis: Bridging basic science and individualized treatment concepts. F1000Research 7. https:\/\/doi.org\/10.12688\/f1000research.14841.1 (2018).","DOI":"10.12688\/f1000research.14841.1"},{"key":"90263_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.14218\/JCTH.2017.00054","volume":"6","author":"BL Woolbright","year":"2018","unstructured":"Woolbright, B. L. & Jaeschke, H. Alcoholic hepatitis: Lost in translation. J. Clin. Transl. Hepatol. 6, 89\u201396. https:\/\/doi.org\/10.14218\/JCTH.2017.00054 (2018).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"90263_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gtc.2017.01.004","volume":"46","author":"DE Kleiner","year":"2017","unstructured":"Kleiner, D. E. Drug-induced liver injury: The hepatic pathologist\u2019s approach. Gastroenterol. Clin. N. Am. 46, 273\u2013296. https:\/\/doi.org\/10.1016\/j.gtc.2017.01.004 (2017).","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"90263_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bpg.2011.02.001","volume":"25","author":"M Penz-Osterreicher","year":"2011","unstructured":"Penz-Osterreicher, M., Osterreicher, C. H. & Trauner, M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract. Res. Clin. Gastroenterol. 25, 245\u2013258. https:\/\/doi.org\/10.1016\/j.bpg.2011.02.001 (2011).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"90263_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2004-823098","volume":"24","author":"EM Brunt","year":"2004","unstructured":"Brunt, E. M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24, 3\u201320. https:\/\/doi.org\/10.1055\/s-2004-823098 (2004).","journal-title":"Semin. Liver Dis."},{"key":"90263_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/1535370214532596","volume":"239","author":"AM Clark","year":"2014","unstructured":"Clark, A. M. et al. A microphysiological system model of therapy for liver micrometastases. Exp. Biol. Med. 239, 1170\u20131179. https:\/\/doi.org\/10.1177\/1535370214532596 (2014).","journal-title":"Exp. Biol. Med."},{"key":"90263_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1096\/fasebj.8.11.7520879","volume":"8","author":"EJ Kovacs","year":"1994","unstructured":"Kovacs, E. J. & DiPietro, L. A. Fibrogenic cytokines and connective tissue production. FASEB J. 8, 854\u2013861 (1994).","journal-title":"FASEB J."},{"key":"90263_CR9","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","volume":"22","author":"CY Zhang","year":"2016","unstructured":"Zhang, C. Y., Yuan, W. G., He, P., Lei, J. H. & Wang, C. X. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J. Gastroenterol. 22, 10512\u201310522. https:\/\/doi.org\/10.3748\/wjg.v22.i48.10512 (2016).","journal-title":"World J. Gastroenterol."},{"key":"90263_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41467-017-01169-0","volume":"8","author":"NP Dufton","year":"2017","unstructured":"Dufton, N. P. et al. Dynamic regulation of canonical TGFbeta signalling by endothelial transcription factor ERG protects from liver fibrogenesis. Nat. Commun. 8, 895. https:\/\/doi.org\/10.1038\/s41467-017-01169-0 (2017).","journal-title":"Nat. Commun."},{"key":"90263_CR11","doi-asserted-by":"publisher","first-page":"36750","DOI":"10.1038\/srep36750","volume":"6","author":"Y Song","year":"2016","unstructured":"Song, Y. et al. Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. Sci. Rep. 6, 36750. https:\/\/doi.org\/10.1038\/srep36750 (2016).","journal-title":"Sci. Rep."},{"key":"90263_CR12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1043\/1543-2165(2007)131[1728:HSCALF]2.0.CO;2","volume":"131","author":"RK Moreira","year":"2007","unstructured":"Moreira, R. K. Hepatic stellate cells and liver fibrosis. Arch. Pathol. Lab. Med. 131, 1728\u20131734. https:\/\/doi.org\/10.1043\/1543-2165(2007)131[1728:HSCALF]2.0.CO;2 (2007).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"90263_CR13","doi-asserted-by":"publisher","unstructured":"Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M. C. & Ten Dijke, P. TGF-beta-induced endothelial-mesenchymal transition in fibrotic diseases. Int. J. Mol. Sci. 18. https:\/\/doi.org\/10.3390\/ijms18102157 (2017).","DOI":"10.3390\/ijms18102157"},{"key":"90263_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-019-1050-1","volume":"38","author":"SH Kim","year":"2019","unstructured":"Kim, S. H., Song, Y. & Seo, H. R. GSK-3beta regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models. J. Exp. Clin. Cancer Res. (CR) 38, 46. https:\/\/doi.org\/10.1186\/s13046-019-1050-1 (2019).","journal-title":"J. Exp. Clin. Cancer Res. (CR)"},{"key":"90263_CR15","doi-asserted-by":"publisher","first-page":"21650","DOI":"10.18632\/oncotarget.15521","volume":"8","author":"Y Song","year":"2017","unstructured":"Song, Y. et al. TGF-beta-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC. Oncotarget 8, 21650\u201321662. https:\/\/doi.org\/10.18632\/oncotarget.15521 (2017).","journal-title":"Oncotarget"},{"key":"90263_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583\u2013592. https:\/\/doi.org\/10.1038\/nrc1893 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"90263_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser, F. et al. Multicellular tumor spheroids: An underestimated tool is catching up again. J. Biotechnol. 148, 3\u201315. https:\/\/doi.org\/10.1016\/j.jbiotec.2010.01.012 (2010).","journal-title":"J. Biotechnol."},{"key":"90263_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s12885-016-2816-x","volume":"16","author":"JW Jang","year":"2016","unstructured":"Jang, J. W. et al. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes. BMC Cancer 16, 810. https:\/\/doi.org\/10.1186\/s12885-016-2816-x (2016).","journal-title":"BMC Cancer"},{"key":"90263_CR19","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/s41598-018-34301-1","volume":"8","author":"Y Song","year":"2018","unstructured":"Song, Y., Kim, I. K., Choi, I., Kim, S. H. & Seo, H. R. Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133. Sci. Rep. 8, 16100. https:\/\/doi.org\/10.1038\/s41598-018-34301-1 (2018).","journal-title":"Sci. Rep."},{"key":"90263_CR20","doi-asserted-by":"publisher","first-page":"e28053","DOI":"10.1371\/journal.pone.0028053","volume":"6","author":"YS Chen","year":"2011","unstructured":"Chen, Y. S. et al. CD133\/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS ONE 6, e28053. https:\/\/doi.org\/10.1371\/journal.pone.0028053 (2011).","journal-title":"PLoS ONE"},{"key":"90263_CR21","doi-asserted-by":"publisher","first-page":"41499","DOI":"10.1038\/srep41499","volume":"7","author":"K Liu","year":"2017","unstructured":"Liu, K., Hao, M., Ouyang, Y., Zheng, J. & Chen, D. CD133(+) cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma. Sci. Rep. 7, 41499. https:\/\/doi.org\/10.1038\/srep41499 (2017).","journal-title":"Sci. Rep."},{"key":"90263_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-4598-13-15","volume":"13","author":"Q Ding","year":"2014","unstructured":"Ding, Q. et al. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol. Cancer 13, 15. https:\/\/doi.org\/10.1186\/1476-4598-13-15 (2014).","journal-title":"Mol. Cancer"},{"key":"90263_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01324802","volume":"430","author":"ML Hautekeete","year":"1997","unstructured":"Hautekeete, M. L. & Geerts, A. The hepatic stellate (Ito) cell: Its role in human liver disease. Virchows Arch. 430, 195\u2013207 (1997).","journal-title":"Virchows Arch."},{"key":"90263_CR24","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/lt.24412","volume":"22","author":"C Venturi","year":"2016","unstructured":"Venturi, C. et al. Relevance of activated hepatic stellate cells in predicting the development of pediatric liver allograft fibrosis. Liver Transplant. 22, 822\u2013829. https:\/\/doi.org\/10.1002\/lt.24412 (2016).","journal-title":"Liver Transplant."},{"key":"90263_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1183\/09059180.00001111","volume":"20","author":"CJ Schaefer","year":"2011","unstructured":"Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D. & Kossen, K. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20, 85\u201397. https:\/\/doi.org\/10.1183\/09059180.00001111 (2011).","journal-title":"Eur. Respir. Rev."},{"key":"90263_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","volume":"37","author":"L Garcia","year":"2002","unstructured":"Garcia, L. et al. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 37, 797\u2013805 (2002).","journal-title":"J. Hepatol."},{"key":"90263_CR27","first-page":"789","volume":"24","author":"X Lin","year":"2018","unstructured":"Lin, X. et al. Nintedanib inhibits TGF-beta-induced myofibroblast transdifferentiation in human Tenon\u2019s fibroblasts. Mol. Vis. 24, 789\u2013800 (2018).","journal-title":"Mol. Vis."},{"key":"90263_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/2211-5463.12552","volume":"9","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. Identification of radiation-induced EndMT inhibitors through cell-based phenomic screening. FEBS Open Bio 9, 82\u201391. https:\/\/doi.org\/10.1002\/2211-5463.12552 (2019).","journal-title":"FEBS Open Bio"},{"key":"90263_CR29","doi-asserted-by":"publisher","unstructured":"Sircana, A., Paschetta, E., Saba, F., Molinaro, F. & Musso, G. Recent insight into the role of fibrosis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. Int. J. Mol. Sci. 20. https:\/\/doi.org\/10.3390\/ijms20071745 (2019).","DOI":"10.3390\/ijms20071745"},{"key":"90263_CR30","doi-asserted-by":"publisher","unstructured":"Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology 158, 1611\u20131625 e1612. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043 (2020).","DOI":"10.1053\/j.gastro.2020.01.043"},{"key":"90263_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-015-0437-3","volume":"75","author":"C Filozof","year":"2015","unstructured":"Filozof, C., Goldstein, B. J., Williams, R. N. & Sanyal, A. Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 75, 1373\u20131392. https:\/\/doi.org\/10.1007\/s40265-015-0437-3 (2015).","journal-title":"Drugs"},{"key":"90263_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/hep.23123","volume":"50","author":"Y Popov","year":"2009","unstructured":"Popov, Y. & Schuppan, D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50, 1294\u20131306. https:\/\/doi.org\/10.1002\/hep.23123 (2009).","journal-title":"Hepatology"},{"key":"90263_CR33","doi-asserted-by":"publisher","unstructured":"Abenavoli, L., Falalyeyeva, T., Boccuto, L., Tsyryuk, O. & Kobyliak, N. Obeticholic acid: A new era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals (Basel) 11. https:\/\/doi.org\/10.3390\/ph11040104 (2018).","DOI":"10.3390\/ph11040104"},{"key":"90263_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba, R. et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 67, 549\u2013559. https:\/\/doi.org\/10.1002\/hep.29514 (2018).","journal-title":"Hepatology"},{"key":"90263_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13543784.2020.1718106","volume":"29","author":"S Lefere","year":"2020","unstructured":"Lefere, S., Devisscher, L. & Tacke, F. Targeting CCR2\/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: Opportunities and challenges. Expert Opin. Investig. Drugs 29, 89\u201392. https:\/\/doi.org\/10.1080\/13543784.2020.1718106 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"90263_CR36","doi-asserted-by":"publisher","unstructured":"Rockey, D. C. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 12, 939\u2013962, xi. https:\/\/doi.org\/10.1016\/j.cld.2008.07.011 (2008).","DOI":"10.1016\/j.cld.2008.07.011"},{"key":"90263_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.14218\/JCTH.2020.00026","volume":"8","author":"Y Chang","year":"2020","unstructured":"Chang, Y. & Li, H. Hepatic antifibrotic pharmacotherapy: Are we approaching success?. J. Clin. Transl. Hepatol. 8, 222\u2013229. https:\/\/doi.org\/10.14218\/JCTH.2020.00026 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"90263_CR38","doi-asserted-by":"publisher","unstructured":"Wells, R. G. Cellular sources of extracellular matrix in hepatic fibrosis. Clin. Liver Dis. 12, 759\u2013768, viii. https:\/\/doi.org\/10.1016\/j.cld.2008.07.008 (2008).","DOI":"10.1016\/j.cld.2008.07.008"},{"key":"90263_CR39","doi-asserted-by":"publisher","unstructured":"Rehman, M. et al. High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation. JCI insight 4. https:\/\/doi.org\/10.1172\/jci.insight.123987 (2019).","DOI":"10.1172\/jci.insight.123987"},{"key":"90263_CR40","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1073\/pnas.1702750114","volume":"114","author":"MJ Bollong","year":"2017","unstructured":"Bollong, M. J. et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc. Natl. Acad. Sci. U.S.A. 114, 4679\u20134684. https:\/\/doi.org\/10.1073\/pnas.1702750114 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"90263_CR41","doi-asserted-by":"publisher","first-page":"7942614","DOI":"10.1155\/2018\/7942614","volume":"2018","author":"XT Wang","year":"2018","unstructured":"Wang, X. T. et al. Establishing a cell-based high-content screening assay for TCM compounds with anti-renal fibrosis effects. Evid.-Based Complement. Altern. Med. (eCAM) 2018, 7942614. https:\/\/doi.org\/10.1155\/2018\/7942614 (2018).","journal-title":"Evid.-Based Complement. Altern. Med. (eCAM)"},{"key":"90263_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fphar.2018.00006","volume":"9","author":"SA Langhans","year":"2018","unstructured":"Langhans, S. A. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol. 9, 6. https:\/\/doi.org\/10.3389\/fphar.2018.00006 (2018).","journal-title":"Front. Pharmacol."},{"key":"90263_CR43","doi-asserted-by":"publisher","first-page":"e0162394","DOI":"10.1371\/journal.pone.0162394","volume":"11","author":"K Arai","year":"2016","unstructured":"Arai, K. et al. A novel high-throughput 3D screening system for EMT inhibitors: A pilot screening discovered the EMT inhibitory activity of CDK2 inhibitor SU9516. PLoS ONE 11, e0162394. https:\/\/doi.org\/10.1371\/journal.pone.0162394 (2016).","journal-title":"PLoS ONE"},{"key":"90263_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.yexcr.2015.10.003","volume":"339","author":"C Wenzel","year":"2015","unstructured":"Wenzel, C., Otto, S., Prechtl, S., Parczyk, K. & Steigemann, P. A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates. Exp. Cell Res. 339, 35\u201343. https:\/\/doi.org\/10.1016\/j.yexcr.2015.10.003 (2015).","journal-title":"Exp. Cell Res."},{"key":"90263_CR45","doi-asserted-by":"publisher","first-page":"F631","DOI":"10.1152\/ajprenal.00379.2006","volume":"293","author":"Q Xu","year":"2007","unstructured":"Xu, Q., Norman, J. T., Shrivastav, S., Lucio-Cazana, J. & Kopp, J. B. In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am. J. Physiol. Renal Physiol. 293, F631-640. https:\/\/doi.org\/10.1152\/ajprenal.00379.2006 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"90263_CR46","doi-asserted-by":"publisher","DOI":"10.3791\/55159","author":"SF Boj","year":"2017","unstructured":"Boj, S. F. et al. Forskolin-induced swelling in intestinal organoids: an in vitro assay for assessing drug response in cystic fibrosis patients. J. Vis. Exp. (JoVE) https:\/\/doi.org\/10.3791\/55159 (2017).","journal-title":"J. Vis. Exp. (JoVE)"},{"key":"90263_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbrc.2017.11.049","volume":"495","author":"S Park","year":"2018","unstructured":"Park, S. et al. GOLGA2 loss causes fibrosis with autophagy in the mouse lung and liver. Biochem. Biophys. Res. Commun. 495, 594\u2013600. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.049 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"90263_CR48","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.3748\/wjg.v23.i42.7495","volume":"23","author":"A Eshraghian","year":"2017","unstructured":"Eshraghian, A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J. Gastroenterol. 23, 7495\u20137504. https:\/\/doi.org\/10.3748\/wjg.v23.i42.7495 (2017).","journal-title":"World J. Gastroenterol."},{"key":"90263_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/1319-3767.178527","volume":"22","author":"A Dajani","year":"2016","unstructured":"Dajani, A. & AbuHammour, A. Treatment of nonalcoholic fatty liver disease: Where do we stand? An overview. Saudi J. Gastroenterol. 22, 91\u2013105. https:\/\/doi.org\/10.4103\/1319-3767.178527 (2016).","journal-title":"Saudi J. Gastroenterol."},{"key":"90263_CR50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jcp.25921","volume":"233","author":"H Shimizu","year":"2018","unstructured":"Shimizu, H., Tsubota, T., Kanki, K. & Shiota, G. All-trans retinoic acid ameliorates hepatic stellate cell activation via suppression of thioredoxin interacting protein expression. J. Cell. Physiol. 233, 607\u2013616. https:\/\/doi.org\/10.1002\/jcp.25921 (2018).","journal-title":"J. Cell. Physiol."},{"key":"90263_CR51","unstructured":"Senoo, H. & Wake, K. Suppression of experimental hepatic fibrosis by administration of vitamin A. Lab. Invest. J. Technic. Methods Pathol. 52, 182\u2013194 (1985)."},{"key":"90263_CR52","first-page":"295","volume":"33","author":"JG Parkes","year":"2003","unstructured":"Parkes, J. G. & Templeton, D. M. Effects of retinol and hepatocyte-conditioned medium on cultured rat hepatic stellate cells. Ann. Clin. Lab. Sci. 33, 295\u2013305 (2003).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"90263_CR53","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00383-011-2853-0","volume":"27","author":"K Murakami","year":"2011","unstructured":"Murakami, K. et al. Therapeutic effects of vitamin A on experimental cholestatic rats with hepatic fibrosis. Pediatr. Surg. Int. 27, 863\u2013870. https:\/\/doi.org\/10.1007\/s00383-011-2853-0 (2011).","journal-title":"Pediatr. Surg. Int."},{"key":"90263_CR54","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/bph.13611","volume":"173","author":"NN El-Agroudy","year":"2016","unstructured":"El-Agroudy, N. N., El-Naga, R. N., El-Razeq, R. A. & El-Demerdash, E. Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride-induced liver fibrosis in rats. Br. J. Pharmacol. 173, 3248\u20133260. https:\/\/doi.org\/10.1111\/bph.13611 (2016).","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl","key":"90263_CR55","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jhep.2004.12.008","volume":"42","author":"M Pinzani","year":"2005","unstructured":"Pinzani, M., Rombouts, K. & Colagrande, S. Fibrosis in chronic liver diseases: Diagnosis and management. J. Hepatol. 42(Suppl), S22-36. https:\/\/doi.org\/10.1016\/j.jhep.2004.12.008 (2005).","journal-title":"J. Hepatol."},{"key":"90263_CR56","doi-asserted-by":"publisher","unstructured":"Dewidar, B., Meyer, C., Dooley, S. & Meindl-Beinker, A. N. TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells 8. https:\/\/doi.org\/10.3390\/cells8111419 (2019).","DOI":"10.3390\/cells8111419"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90263-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90263-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90263-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:43:05Z","timestamp":1670056985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90263-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90263-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10931"}}